Issues - Gennaio 2025

Jhaveri KL, Neven P, Casalnuovo ML, et al.

Imlunestrant with or without abemaciclib in advanced breast cancer

N Engl J Med 2024 Dec 11. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract | Scarica ppt

---

Kalinsky K, Bianchini G, Hamilton E, et al.

Abemaciclib plus fulvestrant in advanced breast cancer following progression on CDK4/6 inhibition: results from the phase III postMONARCH trial

J Clin Oncol 2024 Dec 18:JCO2402086. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract | Scarica ppt

---

Sonke GS, van Ommen-Nijhof A, Wortelboer N, et al.

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Nature 2024;636(8042):474-480

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract | Scarica ppt

---

Reimer T, Stachs A, Veselinovic K, et al.

Axillary surgery in breast cancer – Primary results of the INSEMA trial

N Engl J Med 2024 Dec 12. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract | Scarica ppt

---

Pusztai L, Hoag JR, Albain KS, et al.

Development and validation of the RSClinN+ tool to predict prognosis and chemotherapy benefit for hormone receptor-positive, node-positive breast cancer

J Clin Oncol 2024 Dec 2:JCO2401507. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract | Scarica ppt

---

Chen XC, Jiao DC, Qiao JH, et al.

De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial

Lancet Oncol 2024 Nov 26:S1470-2045(24)00581-3

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Han HS, Aldrich AL, Garg SK, et al.

Alteration of the tumor microenvironment with intratumoral dendritic cells before chemotherapy in ERBB2 breast cancer: a nonrandomized clinical trial

JAMA Oncol 2024 Dec 5:e245371. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Palmér S, Valachis A, Lindman H, et al.

Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer

J Natl Cancer Inst 2024 Dec 4:djae315

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Bargon CA, Mink Van Der Molen DR, Young-Afat DA, et al.

Clinical and patient-reported outcomes after oncoplastic versus conventional breast conserving surgery-a longitudinal, multicenter cohort study

J Natl Cancer Inst 2024 Nov 29:djae310

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Milano M, Valenza C, Ferrari A, et al.

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer

Eur J Cancer 2024 Dec 6;215:115164. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Partridge AH, Hyslop T, Rosenberg SM, et al.

Patient-reported outcomes for low-risk ductal carcinoma in situ: a secondary analysis of the COMET randomized clinical trial

JAMA Oncol 2024 Dec 12. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Meattini I, De Santis MC, Visani L, et al.

Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial

Lancet Oncol 2024 Dec 11:S1470-2045(24)00661-2

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Chen L, Li H, Zhang H, et al.

Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer: the CamRelief randomized clinical trial

JAMA 2024 Dec 13. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Ho AY, Shiao S, Kobald SA, et al.

PEARL: a phase ib/ii biomarker study of adding radiation therapy to pembrolizumab before neoadjuvant chemotherapy in human epidermal growth factor receptor 2-negative breast cancer

J Clin Oncol 2024;42(36):4282-4293

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Dennis N, Dunton K, Livings C, et al.

Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial

Eur J Cancer 2024; Volume 0, Issue 0, 115192. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Mosher CE, Lee S, Addington EL, et al.

Randomized controlled trial of acceptance and commitment therapy for fatigue interference with functioning in metastatic breast cancer

J Clin Oncol 2024 Oct 25:JCO2400965. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract | Scarica ppt

---

Oliveira M, Pominchuk D, Nowecki Z, et al.

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial

Lancet Oncol 2024;25(11):1424-1439

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract | Scarica ppt

---

Montagna G, Laws A, Ferrucci M, et al.

Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05/ICARO study

J Clin Oncol 2024 Nov 7:JCO2401052. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract | Scarica ppt

---

Turner NC, Im SA, Saura C, et al.

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

N Engl J Med 2024;391(17):1584-1596

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract | Scarica ppt

---

Romanos-Nanclares A, Willett WC, Rosner B, et al.

Proinflammatory dietary pattern and risk of total and subtypes of breast cancer among U.S. women

J Natl Cancer Inst 2024 Nov 20:djae301. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract | Scarica ppt

---

Huppert LA, Wolf D, Yau C, et al.

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Ann Oncol 2024 Oct 28:S0923-7534(24)04070-5. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

---

de Azambuja E, Piccart-Gebhart M, et al.

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

ESMO Open 2024;9(11):103938

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

---

Molinelli C, Bruzzone M, Blondeaux E, et al.

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: a real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Eur J Cancer 2024 Nov 4;213:115113. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

---

Johnson HM, Song J, Warneke CL, et al.

Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy

Cancer 2024 Oct 29. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

---

Brufsky A, Kwan ML, Sandin R, et al.

Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer

Breast Cancer Res Treat 2024;208(2):223-235

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

---

Zhang Q, Freeman JQ, Zhao F, et al.

Clinical Outcomes and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Breast Cancer With Uncommon In Situ Hybridization Patterns or Discordant Immunohistochemistry

J Clin Oncol Advances 2024:1

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

---

Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

---

van ‘t Veer LJ, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al.

Selection of patients with early-stage breast cancer for extended endocrine therapy: a secondary analysis of the IDEAL randomized clinical trial

JAMA Netw Open 2024;7(11):e2447530

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

---

Melink Z, Lustberg MB, Schnell PM, et al.

Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trial

Breast Cancer Res Treat 2024;208(3):605-617

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

---

Awan AA, Stober C, Pond GR, et al.

A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer

Breast Cancer Res Treat 2024;208(3):523-533

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

---

Phillips KA, Kotsopoulos J, Domchek SM, et al.

Hormonal contraception and breast cancer risk for carriers of germline mutations in BRCA1 and BRCA2

J Clin Oncol 2024 Oct 2:JCO2400176. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract | Scarica ppt

---

Wu AH, Wu J, Tseng C, et al.

Air pollution and breast cancer incidence in the multiethnic cohort study

J Clin Oncol 2024 Oct 8:JCO2400418. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract | Scarica ppt

---

Kim DH, Théberge V, Parpia S, et al.

OPAR: a randomized trial of partial breast irradiation in five fractions once daily for early breast cancer

J Clin Oncol 2024 Oct 8:JCO2400600. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract | Scarica ppt

---

Turner N, Saura C, Aftimos p, et al.

Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: an open-label, randomized, phase III trial (TULIP)

J Clin Oncol 2024 Oct 23:JCO2400529. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract | Scarica ppt

---

Jensen MB, Balslev E, Knoop AS, et al.

Adjuvant docetaxel and cyclophosphamide with or without epirubicin for early breast cancer: final analysis of the randomized DBCG 07-READ trial

J Clin Oncol 2024 Oct 23:JCO2400836. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract | Scarica ppt

---

Hortobagyi GN, Lacko A, Sohn J, et al.

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial

Ann Oncol 2024 Oct 21:S0923-7534(24)04064-X. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Hiensch AE, Depenbusch J, Schmidt ME, et al.

Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial

Nat Med 2024;30(10):2957-2966

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Watts EL, Moore SC, Abar L, et al.

Physical activity, metabolites, and breast cancer associations

J Natl Cancer Inst 2024 Oct 9:djae246. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

John EM, Koo J, Ingles SA, et al.

Risk factors for second primary breast cancer by laterality, age, and race and ethnicity

J Natl Cancer Inst 2024 Oct 11:djae254. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Nader-Marta G, Singer C, Hlauschek D, et al.

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

Breast Cancer Res 2024;26(1):140

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Gjesvik J, Moshina N, Lee CI, et al.

Artificial intelligence algorithm for subclinical breast cancer detection

JAMA Netw Open 2024;7(10):e2437402

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Gannon MR, Dodwell D, Miller K, et al.

Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: a national population-based cohort study using routine data

Eur J Cancer 2024;211:114309

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Kimmick G, Pilehvari A, You W, et al.

First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting

Breast Cancer Res Treat 2024;208(2):263-273

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Pilehvari A, Kimmick G, You W, et al.

Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting

Breast Cancer Res 2024;26(1):144

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Schmid P, Cortes J, Dent R, et al.

Overall survival with pembrolizumab in early-stage triple-negative breast cancer

N Engl J Med 2024 Sep 15. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Bardia A, Hu X, Dent R, et al.

Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer

N Engl J Med 2024 Sep 15. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

De Sanctis R, Tiberio P, Jacobs F, et al.

Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer

Oncologist 2024;29(9):e1113-e1119

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Qureshi Z, Jamil A, Fatima E, et al.

Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: a systematic review and meta-analysis

Am J Clin Oncol 2024 Sep 9. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Dilawari A, Buturla J, Osgood C, et al.

US Food and Drug Administration approval summary: capivasertib with fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN alterations

J Clin Oncol 2024 Aug 19:JCO2400427. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Oliveira M, Rugo HS, Howell SJ, et al.

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Lancet Oncol 2024;25(9):1231-1244

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Zuley ML, Bandos AI, Duffy SW, et al.

Breast cancer screening interval: effect on rate of late-stage disease at diagnosis and overall survival

J Clin Oncol 2024 Aug 21:JCO2400285. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Bardia A, Jhaveri K, Im SA, et al.

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01

J Clin Oncol 2024 Sep 12:JCO2400920. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Loibl S, Jassem J, Sonnenblick A, et al.

Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update

J Clin Oncol 2024 Sep 11:JCO2302505. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Jhaveri KL, Lim E, Jeselsohn R, et al.

Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: phase Ia/Ib EMBER Study

J Clin Oncol 2024 Sep 6:JCO2302733. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Geurts VCM, Balduzzi S, Steenbruggen TG, et al.

Tumor-infiltrating lymphocytes in patients with stage i triple-negative breast cancer untreated with chemotherapy

JAMA Oncol 2024;10(8):1077-1086

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Park KU, Lipsitz S, Dominici LS, et al.

Generative artificial intelligence as a source of breast cancer information for patients: proceed with caution

Cancer 2024 Aug 30. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

André F, Cortés J, Curigliano G, et al.

A pooled analysis of trastuzumab deruxtecan in patients with her2-positive metastatic breast cancer with brain metastases

Ann Oncol 2024 Sep 4:S0923-7534(24)03928-0. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Pagliuca M, Havas J, Thomas E, et al.

Long-term behavioral symptom clusters among survivors of early-stage breast cancer. Development and validation of a predictive model

J Natl Cancer Inst 2024 Sep 9:djae222. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

André F, Solovieff N, Su F, et al.

Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

Ann Oncol 2024 Sep 21:S0923-7534(24)04018-3. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Patel BK, Carnahan MB, Northfelt D, et al.

Prospective study of supplemental screening with contrast-enhanced mammography in women with elevated risk of breast cancer: results of the prevalence round

J Clin Oncol 2024 Jul 26:JCO2202819. Epub ahead of print

Simonpietro Marrocco Settembre 2024

Leggi abstract | Scarica ppt

---

Rastogi P, Bandos H, Lucas PC, et al.

Utility of the 70-Gene MammaPrint assay for prediction of benefit from extended letrozole therapy in the NRG Oncology/NSABP B-42 trial

J Clin Oncol 2024 Jul 24:JCO2301995. Epub ahead of print

Simonpietro Marrocco Settembre 2024

Leggi abstract | Scarica ppt

---

Di Meglio A, Havas J, Pagliuca M, et al.

A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance two years later

Ann Oncol 2024 Aug 2:S0923-7534(24)01517-5. Epub ahead of print

Simonpietro Marrocco Settembre 2024

Leggi abstract | Scarica ppt

---

de Boniface J, Appelgren M, Szulkin R, et al.

Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial

Lancet Oncol 2024;25(9):1222-1230

Simonpietro Marrocco Settembre 2024

Leggi abstract | Scarica ppt

---

Williams LJ, Kunkler IH, Taylor KJ, et al.

Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial

Lancet Oncol 2024;25(9):1213-1221

Simonpietro Marrocco Settembre 2024

Leggi abstract | Scarica ppt

---

Giannakeas V, Lim DW, Narod SA

Bilateral mastectomy and breast cancer mortality

JAMA Oncol 2024 Jul 25:e242212. Epub ahead of print

Simonpietro Marrocco Settembre 2024

Leggi abstract

---

Massa D, Vernieri C, Nicolè L, et al.

Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer

J Natl Cancer Inst 2024 Jul 31:djae178. Epub ahead of print

Simonpietro Marrocco Settembre 2024

Leggi abstract

---

Wong JS, Uno H, Tramontano AC, et al.

Hypofractionated vs conventionally fractionated postmastectomy radiation after implant-based reconstruction: a randomized clinical trial

JAMA Oncol 2024 Aug 8:e242652. Epub ahead of print

Simonpietro Marrocco Settembre 2024

Leggi abstract

---

O’Regan RM, Zhang Y, Fleming GF, et al.

Breast cancer index in premenopausal women with early-stage hormone receptor-positive breast cancer

JAMA Oncol 2024 Aug 15:e243044. Epub ahead of print

Simonpietro Marrocco Settembre 2024

Leggi abstract

---

Poggio F, Blondeaux E, Tagliamento M, et al.

Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial

ESMO Open 2024;9(8):103650

Simonpietro Marrocco Settembre 2024

Leggi abstract

---

Chapman JW, Bayani J, SenGupta S, et al.

Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole

J Clin Oncol 2024;42(24):2887-2898

Simonpietro Marrocco Settembre 2024

Leggi abstract

---

Zuo W, Wang Z, Qian J, et al.

QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial

Br J Cancer 2024;131(4):668-675

Simonpietro Marrocco Settembre 2024

Leggi abstract

---

Dent RA, Kim SB, Oliveira M, et al.

Ipatasertib plus paclitaxel for patients with PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer in the IPATunity130 Phase III trial

Clin Cancer Res 2024 Jul 26. Epub ahead of print

Simonpietro Marrocco Settembre 2024

Leggi abstract

---

Schick A, Hardy S, Strawderman M, et al.

Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (the SYBRA study)

NPJ Breast Cancer 2024;10(1):69

Simonpietro Marrocco Settembre 2024

Leggi abstract

---

Bardia A, Cortes J, Bidard FC, et al.

Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 Inhibitor and in clinical subgroups

Clin Cancer Res 2024 Aug 1. Epub ahead of print

Simonpietro Marrocco Settembre 2024

Leggi abstract

---

Ramchand SK, Ghasem-Zadeh A, Hoermann R, et al.

Denosumab prevents bone loss and microarchitectural deterioration in premenopausal women with breast cancer receiving estradiol suppression therapy: a randomized controlled trial

J Clin Oncol 2024 Jul 2:JCO2302309. Epub ahead of print

Simonpietro Marrocco Agosto 2024

Leggi abstract | Scarica ppt

---

Hahn E, Sutradhar R, Paszat L, et al.

Molecular expression assays improve the prediction of local and invasive local recurrence after breast-conserving surgery for ductal carcinoma in situ

J Clin Oncol 2024 Jun 28:JCO2302276. Epub ahead of print

Simonpietro Marrocco Agosto 2024

Leggi abstract | Scarica ppt

---

Katz SJ, Abrahamse P, Furgal A, et al.

Genetic counseling, testing, and family communication into survivorship after diagnosis of breast cancer

J Clin Oncol 2024 Jul 15:JCO2400122. Epub ahead of print

Simonpietro Marrocco Agosto 2024

Leggi abstract | Scarica ppt

---

Matikas A, Möbus V, Greil R, et al.

Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: end-of-study results of the randomized PANTHER trial

J Clin Oncol 2024 Jul 17:JCO2400178. Epub ahead of print

Simonpietro Marrocco Agosto 2024

Leggi abstract | Scarica ppt

---

Salim M, Liu Y, Sorkhei M, et al.

AI-based selection of individuals for supplemental MRI in population-based breast cancer screening: the randomized ScreenTrustMRI trial

Nat Med 2024 Jul 8. Epub ahead of print

Simonpietro Marrocco Agosto 2024

Leggi abstract | Scarica ppt

---

Rapp SR, Dressler EV, Brown WM, et al.

Phase III randomized, placebo-controlled clinical trial of donepezil for treatment of cognitive impairment in breast cancer survivors after adjuvant chemotherapy (WF-97116)

J Clin Oncol 2024;42(21):2546-2557

Simonpietro Marrocco Agosto 2024

Leggi abstract

---

Stone PC, Minton O, Richardson A, et al.

Methylphenidate versus placebo for treating fatigue in patients with advanced cancer: randomized, double-blind, multicenter, placebo-controlled trial

J Clin Oncol 2024;42(20):2382-2392

Simonpietro Marrocco Agosto 2024

Leggi abstract

---

Arecco L, Bruzzone M, Bas R, et al.

Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Ann Oncol 2024 Jun 20:S0923-7534(24)00740-3

Simonpietro Marrocco Agosto 2024

Leggi abstract

---

Dent R, Cortés J, Pusztai L, et al.

Neoadjuvant pembrolizumab + chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from randomized KEYNOTE-522 study

J Natl Cancer Inst 2024 Jun 24:djae129

Simonpietro Marrocco Agosto 2024

Leggi abstract

---

Freedman RA, Heiling HM, Li T, et al.

Neratinib and ado-trastuzumab-emtansine for pre-treated and untreated her2-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022

Ann Oncol 2024 Jul 6:S0923-7534(24)01015-9. Epub ahead of print

Simonpietro Marrocco Agosto 2024

Leggi abstract

---

Puklin LS, Ferrucci LM, Harrigan M, et al.

Improving lifestyle behaviors during chemotherapy for breast cancer: the Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) trial

Cancer 2024;130(14):2440-2452

Simonpietro Marrocco Agosto 2024

Leggi abstract

---

Blomqvist C, Vehmanen L, Kellokumpu-Lehtinen PL, et al.

Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study

Breast Cancer Res Treat 2024;206(1):57-65

Simonpietro Marrocco Agosto 2024

Leggi abstract

---

Debien V, Agostinetto E, Bruzzone M, et al.

The impact of initial tumor response on survival outcomes of patients with HER2-positive advanced breast cancer treated with docetaxel, trastuzumab, and pertuzumab: an exploratory analysis of the CLEOPATRA trial

Clin Breast Cancer 2024;24(5):421-430.e3

Simonpietro Marrocco Agosto 2024

Leggi abstract

---

Chung HC, Saada-Bouzid E, Longo F, et al.

Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 study

Cancer 2024 Jun 21. Epub ahead of print

Simonpietro Marrocco Agosto 2024

Leggi abstract

---

Corianò M, Tommasi C, Dinh ATL, et al.

The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study

Breast Cancer Res Treat 2024;206(3):603-614

Simonpietro Marrocco Agosto 2024

Leggi abstract

---

Chavez-MacGregor M, Miao J, Pusztai L, et al.

Phase III randomized, placebo-controlled trial of endocrine therapy ± 1 year of everolimus in patients with high-risk, hormone receptor-positive, early-stage breast cancer

J Clin Oncol 2024 Jun 4:JCO2302344. Epub ahead of print

Simonpietro Marrocco Luglio 2024

Leggi abstract | Scarica ppt

---

Azim HA Jr, Niman SM, Partridge AH, et al.

Fertility preservation and assisted reproduction in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy

J Clin Oncol 2024 May 29:JCO2302292. Epub ahead of print

Simonpietro Marrocco Luglio 2024

Leggi abstract | Scarica ppt

---

Cortés J, Hurvitz SA, O’Shaughnessy J, et al.

Randomized phase iii study of amcenestrant plus palbociclib versus letrozole plus palbociclib in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from AMEERA-5

J Clin Oncol 2024 Jun 18:JCO2302036. Epub ahead of print

Simonpietro Marrocco Luglio 2024

Leggi abstract | Scarica ppt

---

Tarantino p, Tayob N, Villacampa G, et al.

Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage i human epidermal growth factor receptor 2-positive breast cancer: 5-year results and correlative analyses from ATEMPT

J Clin Oncol 2024 Jun 27:JCO2302170. Epub ahead of print

Simonpietro Marrocco Luglio 2024

Leggi abstract | Scarica ppt

---

Dent R, André F, Gonçalves A, et al.

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

Ann Oncol 2024;35(7):630-642

Simonpietro Marrocco Luglio 2024

Leggi abstract | Scarica ppt

---

Xiao Q, Mao X, Ploner A, et al.

Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer

J Natl Cancer Inst 2024;116(6):911-919

Simonpietro Marrocco Luglio 2024

Leggi abstract

---

Ohnstad HO, Blix ES, Akslen LA, et al.

Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)

ESMO Open 2024;9(6):103475

Simonpietro Marrocco Luglio 2024

Leggi abstract

---

Soldato D, Michiels S, Havas J, et al.

Dose/exposure relationship of exercise and distant recurrence in primary breast cancer

J Clin Oncol 2024 Jun 5:JCO2301959. Epub ahead of print

Simonpietro Marrocco Luglio 2024

Leggi abstract

---

Bostany G, Chen Y, Francisco L, et al.

Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors

J Clin Oncol 2024 Jun 4:JCO2301779. Epub ahead of print

Simonpietro Marrocco Luglio 2024

Leggi abstract

---

Martín M, Lim E, Chavez-MacGregor M, et al.

Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study

J Clin Oncol 2024;42(18):2149-2160

Simonpietro Marrocco Luglio 2024

Leggi abstract

---

Cortés J, Hurvitz SA, Im SA, et al.

Trastuzumab deruxtecan vs trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Nat Med 2024 Jun 2. Epub ahead of print

Simonpietro Marrocco Luglio 2024

Leggi abstract

---

Zhang BX, Brantley KD, Rosenberg SM, et al.

Second primary non-breast cancers in young breast cancer survivors

Breast Cancer Res Treat 2024 Jun 10. Epub ahead of print

Simonpietro Marrocco Luglio 2024

Leggi abstract

---

Kang D, Cho J, Zhao D, et al.

Scalp cooling in preventing persistent chemotherapy-induced alopecia: a randomized controlled trial

J Clin Oncol 2024 Jun 6:JCO2302374. Epub ahead of print

Simonpietro Marrocco Luglio 2024

Leggi abstract

---

Chua AV Jr, Sheng H, Liang E, et al.

Epidemiology of early vs late recurrence among women with early-stage estrogen receptor-positive breast cancer in the pathways study

J Natl Cancer Inst 2024 Jun 6:djae128. Epub ahead of print

Simonpietro Marrocco Luglio 2024

Leggi abstract

---

Schmidt JA, Woolpert KM, Hjorth CF, et al.

Social characteristics and adherence to adjuvant endocrine therapy in premenopausal women with breast cancer

J Clin Oncol 2024 Jun 25:JCO2302643. Epub ahead of print

Simonpietro Marrocco Luglio 2024

Leggi abstract

---

Goetz MP, Toi M, Huober J, et al.

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3

Ann Oncol 2024 May 8:S0923-7534(24)00139-X. Epub ahead of print

Simonpietro Marrocco Giugno 2024

Leggi abstract | Scarica ppt

---

Fehm T, Cottone F, Dunton K, et al.

Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial

Lancet Oncol 2024;25(5):614-625

Simonpietro Marrocco Giugno 2024

Leggi abstract | Scarica ppt

---

Mars N, Kerminen S, Tamlander M, et al.

Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women

J Clin Oncol 2024;42(13):1477-1487

Simonpietro Marrocco Giugno 2024

Leggi abstract | Scarica ppt

---

Bardia A, Rugo HS, Tolaney SM, et al.

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

J Clin Oncol 2024;42(15):1738-1744

Simonpietro Marrocco Giugno 2024

Leggi abstract | Scarica ppt

---

Lu YS, Bin Mohd Mahidin EI, Azim H, et al.

Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer

J Clin Oncol 2024 May 21:JCO2400144. Epub ahead of print

Simonpietro Marrocco Giugno 2024

Leggi abstract | Scarica ppt

---

Fernandez-Martinez A, Rediti M, Tang G, et al.

Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials

JAMA Oncol 2024;10(5):603-611

Simonpietro Marrocco Giugno 2024

Leggi abstract

---

Pusztai L, Denkert C, O’Shaughnessy J, et al.

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

Ann Oncol 2024;35(5):429-436

Simonpietro Marrocco Giugno 2024

Leggi abstract

---

Guerini-Rocco E, Bellerba F, Concardi A, et al.

Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ

Eur J Cancer 2024;203:114063

Simonpietro Marrocco Giugno 2024

Leggi abstract

---

Cescon DW, Schmid p, Rugo HS, et al.

Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355

J Natl Cancer Inst 2024;116(5):717-727

Simonpietro Marrocco Giugno 2024

Leggi abstract

---

Penault-Llorca F, Dalenc F, Chabaud S, et al.

Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial

ESMO Open 2024;9(5):103443

Simonpietro Marrocco Giugno 2024

Leggi abstract

---

Chlebowski RT, Aragaki AK, Pan K, et al.

Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women’s Health Initiative

Cancer 2024 May 13. Epub ahead of print

Simonpietro Marrocco Giugno 2024

Leggi abstract

---

Hamilton E, Oliveira M, Turner N, et al.

A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Ann Oncol 2024 May 8:S0923-7534(24)00138-8

Simonpietro Marrocco Giugno 2024

Leggi abstract

---

Epaillard N, Lusque A, Jacot W, et al.

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort

ESMO Open 2024;9(5):103447

Simonpietro Marrocco Giugno 2024

Leggi abstract

---

Haddad TC, Suman VJ, Giridhar KV, et al.

Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early-stage breast cancer: A prospective trial

Clin Cancer Res 2024 May 16. Epub ahead of print

Simonpietro Marrocco Giugno 2024

Leggi abstract

---

de Boniface J, Filtenborg Tvedskov T, Rydén L, et al.

Omitting axillary dissection in breast cancer with sentinel-node metastases

N Engl J Med 2024;390(13):1163-1175

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract | Scarica ppt

---

Ganz PA, Bandos H, Španić T, et al.

Patient-reported outcomes in olympia: a phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer

J Clin Oncol 2024;42(11):1288-1300

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract | Scarica ppt

---

Leon-Ferre RA, Jonas SF, Salgado R, et al.

Tumor-infiltrating lymphocytes in triple-negative breast cancer

JAMA 2024;331(13):1135-1144

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract | Scarica ppt

---

Alaeikhanehshir S, Ajayi T, Duijnhoven FH, et al.

Locoregional breast cancer recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT trial: analysis of risk factors including the 70-gene signature

J Clin Oncol 2024;42(10):1124-1134

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract | Scarica ppt

---

Geyer CE Jr, Blum JL, Yothers G, et al.

Long-term follow-up of the anthracyclines in early breast cancer trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])

J Clin Oncol 2024;42(12):1344-1349

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract | Scarica ppt

---

Williams AD, Ruth K, Shaikh SS, et al.

Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?

Cancer 2024;130(7):1052-1060

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Shah M, Lingam H, Gao X, et al.

US Food and Drug Administration Approval Summary: elacestrant for estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer

J Clin Oncol 2024;42(10):1193-1201

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Tarantino p, Ajari O, Graham N, et al.

Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer

Eur J Cancer 2024;201:113920

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Botticelli A, Caputo R, Scagnoli S, et al.

Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study

Oncologist 2024;29(4):303-310

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Akkoc Mustafayev FN, Shukla MA, Lanier A, et al.

Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations

Cancer 2024;130(9):1600-1608

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Haiderali A, Huang M, Pan W, et al.

Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer

Future Oncol 2024 Apr 10 doi: 10.2217/fon-2023-0301. Epub ahead of print.

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Bardia A, Krop IE, Kogawa T, et al.

Datopotamab deruxtecan in advanced or metastatic HR+/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study

J Clin Oncol 2024 Apr 23:JCO2301909. Epub ahead of print

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Brantley KD, Rosenberg SM, Collins LC, et al.

Second primary breast cancer in young breast cancer survivors

JAMA Oncol 2024 Apr 11:e240286. Epub ahead of print

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

van der Voort A, Louis FM, van Ramshorst MS, et al.

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

Lancet Oncol 2024 Apr 5:S1470-2045(24)00104-9. Epub ahead of print

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

LeVee A, Wong M, Flores S, et al.

Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis

Oncologist 2024 Apr 24:oyae064. Epub ahead of print

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Slamon DJ, Diéras V, Rugo HS, et al.

Overall survival with palbociclib plus letrozole in advanced breast cancer

J Clin Oncol 2024;42(9):994-1000

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract | Scarica ppt

---

Slamon D, Lipatov O, Nowecki Z, et al.

Ribociclib plus endocrine therapy in early breast Cancer

N Engl J Med 2024;390(12):1080-91

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract | Scarica ppt

---

Rastogi P, O’Shaughnessy J, Martin M, et al.

Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes

J Clin Oncol 2024;42(9):987-993

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract | Scarica ppt

---

Hubbard RA, Su YR, Bowles EJ, et al.

Predicting five-year interval second breast cancer risk in women with prior breast cancer

J Natl Cancer Inst 2024 Mar 11:djae063

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract | Scarica ppt

---

Ma CX, Suman VJ, Sanati S, et al.

Endocrine-sensitive disease rate in postmenopausal patients with estrogen receptor-rich/ERBB2-negative breast cancer receiving neoadjuvant anastrozole, fulvestrant, or their combination: a phase 3 randomized clinical trial

JAMA Oncol 2024;10(3):362-371

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract | Scarica ppt

---

Tolaney SM, Guarneri V, Seo JH, et al.

Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer

Eur J Cancer 2024;199:113555

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract

---

Diéras V, Han HS, Wildiers H, et al.

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial

Eur J Cancer 2024;200:113580

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract

---

Saltbæk L, Bidstrup PE, Karlsen RV, et al.

Nurse-led individualized follow-up versus regular physician-led visits after early breast cancer (MyHealth): a phase iii randomized, controlled trial

J Clin Oncol 2024 Mar 18:JCO2301447

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract

---

Loeser A, Kim JS, Peppercorn J, et al.

The right dose: results of a patient advocate-led survey of individuals with metastatic breast cancer regarding treatment-related side effects and views about dosage assessment to optimize quality of life

JCO Oncol Pract 2024 Mar 22:OP2300539

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract

---

Zeng E, He W, Sjölander A, et al.

Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis

J Natl Cancer Inst 2024 Mar 12:djae061

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract

---

Tokunaga E, Miyoshi Y, Dozono K, et al.

Association of neutrophil-to-lymphocyte ratio and absolute lymphocyte count with clinical outcomes in advanced breast cancer in the MONARCH 2 trial

Oncologist 2024;29(3):e319-e329

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract

---

Mayer EL, Ren Y, Wagle N, et al.

PACE: a randomized phase ii study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4/6 inhibitor and aromatase inhibitor for hormone receptor-positive/human epidermal growth factor receptor-negative metastatic breast cancer

J Clin Oncol 2024 Mar 21:JCO2301940

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract

---

Kumar N, Ehsan S, Banerjee S, et al.

The unique risk factor profile of triple negative breast cancer: a comprehensive meta-analysis

J Natl Cancer Inst 2024 Mar 5:djae056

robert.butucaru@medfyle.com Aprile 2024

Leggi abstract

---

Palmieri C, Linden H, Birrell SN, et al.

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial

Lancet Oncol 2024;25(3):317-325

Simonpietro Marrocco Aprile 2024

Leggi abstract

---

Rezaei SJ, Eid E, Tang JY, et al.

Incidence of Nonkeratinocyte Skin Cancer After Breast Cancer Radiation Therapy

JAMA Netw Open 2024;7(3):e241632

Simonpietro Marrocco Aprile 2024

Leggi abstract

---